Form 4: Kronos Bio Director, Katherine V Stultz, Acquires 34,000 Stock Options

Katherine V Stultz, a director of Kronos Bio, Inc., acquired 34,000 stock options on June 25, 2024, exercisable for common stock.

Summary

• On June 25, 2024, Katherine V Stultz, a director of Kronos Bio, Inc., acquired 34,000 stock options.
• The exercise price of these options is $0.95.
• The options vest upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
• The options expire on June 24, 2034.
• Following the transaction, Stultz directly owns 34,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency regarding insider transactions. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates